



presented MND syndrome2. Recently, Nanetti et al.3 de-
scribed another 66 year-old woman with SCA2 affected 
with progressive weakness and fasciculation3. Our pa-
tient was younger than the previous reports and pre-
sented MND disease shortly after SCA2 diagnosis.
In 2006, the 43-kDa TAR DNA binding protein 
(TDP-43) was identified as the major disease protein in 
ALS and frontotemporal lobar degeneration with ubiqui-
nated inclusions4. Recently, Elden et al.5 pointed out to 
ATXN2 gene as a relatively common suitability gene to 
ALS. They demonstrated that ATXN2 is a potent modi-
fier of TDP-43 toxicity in animal and cellular models. In 
addition, 6 patients with ALS were evaluated and dis-
closed different ATXN2 localization in spinal cord5. 
This report highlights that unusual phenotypes such 
as an ataxia-parkinsonism-motor neuron disease syn-
drome may be found in SCA 2 individuals. This raises 
several questions such as whether or not patients inves-
tigating MND with or without known family members 
with cerebellar ataxia should be routinely screened for 
ATXN2. Future studies with larger series are welcome to 
address these questions.
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Facial grimacing as a clue for the diagnosis 
of GM1 type 3 gangliosidosis
Ricardo Oliveira Horta Maciel1, José Luiz Pedroso2, Orlando G.P. Barsottini3
GM1 Gangliosidosis is an autosomal recessive lyso-
somal storage disease caused by the deficiency of beta-
galactosidase. Only few cases have been reported in the 
literature, owing to the rarity of the condition but also 
possibly due to its underrecognition in clinical practice1,2. 
Reports of GM1 gangliosidosis type 3 patients and recent 
literature review shows that oromandibular dystonia pro-
ducing the aprearance of grimacing is a common feature 
of this disorder2. Herein we describe a patient in wich 
proeminent facial grimacing served as a clue to the di-
agnosis of GM1 gangliosidosis type 3. The patients legal 
guardian gave consent to publish this case.
A 20 year-old female patient had a normal develop-
ment until the age of 3 years, when the parents noted 
speech impairment wich worsened to the point of in-
inteligibility in the following years. With 5 years cog-
nitive deterioration in other areas was noted and the 
child was never able to attend school. Gait abnormality 
also developed and by the age 11 she was unable to walk 
or stand. On examination the patient had short stature 
and moderate thoracic kyphosis. Tongue and orofacial 
dystonia where present, giving the appearance of gri-
macing (Figure). There was also dystonia of the feet, dys-
tonic posturing of the hands while at rest and increased 
tonus in the legs. No bradykynesia or dysmetria were 
noted. Strenght was normal with brisk reflexes and flexor 
plantar responses. There was no corneal clouding. Slit-
lamp examination and fundoscopy were normal. Bone 
radiographies revealed kyphoscoliosis and femoral dys-
plasia. Routine brain MRI showed T2 hypointensity of 
the globus pallidus and hydrocephalus caused by a in-
cidental ependimoma of the fourth ventricule. Routine 
blood and CSF examination were unremarkable. An ab-
dominal ultrasound showed no abnormalities. Beta-gli-
curonidase, galacto-6-sulphatase and hexosaminidase A 
(testing for mucopolysaccharidosis IV, VII and Tay-Sachs 
disease, respectively) were normal. Leukocyte beta-ga-




mg (normal range 78-280), confirming the diagnosis of 
GM1 Gangliosidosis. 
Type 3 GM1 gangliosidosis is characterized by onset 
around the second decade of life with slowly progres-
sive extrapiramidal signs, such as dystonia and parkin-
sonism1. There is also a high prevalence of gait distur-
bance and dysarthria. Other symptoms are short stature, 
bone abnormalities, cognitive impairment, ataxia and 
cardiac disorders3. Orofacial dystonia is a common fea-
ture of type 3 GM1 gangliosidosis, with a prevalence of 
87.5% according to a recent report2. 
Facial dystonia with proeminent involvement of oro-
mandibular muscles is a frequent manifestation of neuro-
leptic induced movement disorders4,5. However, there is 
also a number of dystonia syndromes in wich proeminet 
orofacial involvement occur, and their presence should 
alert the clinician to their possibility (Table). 
We suggest that in patients with early-onset dys-
tonia, the occurance of facial grimacing should lead to 
the consideration of type 3 GM1 gangliosidosis, particu-
larly when associated with speech and cognitive impair-
ment, gait disturbances and bone abnormalities.
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Table. Causes of facial dystonia.
Neurodegenerative causes Secondary
Progressive supranuclear palsy Drug induced (e.g. 
Neuroleptics, levodopa)
Multiple system atrophy Peripherally-induced 
(e.g. after local trauma)
Corticobasal degeneration Vascular (e.g. thalamic 
hemorrhage)
Wilson disease Paraneoplastic (e.g. 
anti-Ri, anti-NMDA)
Neuroacanthocytosis Autoimmune (e.g. 
Sjoegren syndrome, APL)
Neuroferritinopathy Psychogenic (e.g. fixed 
dystonia of the lower lip)
PKAN
Lesch-Nyhan disease
Figure.  Facial  gr i -
macing and tongue 
dystonia.
Huntington’s disease presenting as 
posterior cortical atrophy
Leonardo Caixeta
Neuroimaging and neuropathological studies on 
Huntington’s disease (HD) have historically focused on 
striatal atrophy1. In posterior cortical atrophy (PCA), 
there is a progressive impairment of high-level visual 
functions and parietal damage2. The conundrum of PCA 
is that while the clinical presentation is relatively homo-
geneous, the nosological status remains something of a 
puzzle. We report a case of HD presenting as PCA.
